Snowball logo
logo
RTQ1

AVACTA GROUP PLC LS-10

€0.73-€0.005  (0.68%)
Estimate
EPS
-0.11
Beta
-0.109
About the company
Ticker
RTQ1
ISIN
GB00BYYW9G87
Country
United Kingdom
Sector (GICS)
Healthcare
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.

Frequently asked questions

What sector does AVACTA GROUP PLC LS-10 (RTQ1) operate in?

AVACTA GROUP PLC LS-10 belongs to the Healthcare sector and operates in the Biotechnology industry.

What is AVACTA GROUP PLC LS-10 (RTQ1) current stock price?

As of the latest data, AVACTA GROUP PLC LS-10 stock price is €0.73, with a previous close of €0.74. AVACTA GROUP PLC LS-10 lost -€0.01 in the last trading session, representing a -0.68% loss.

What is AVACTA GROUP PLC LS-10 (RTQ1) current market capitalization?

AVACTA GROUP PLC LS-10 market cap is approximately 342.04 million.

What is AVACTA GROUP PLC LS-10 (RTQ1) Earnings Per Share (EPS)?

The trailing EPS is -€0.11.

Does AVACTA GROUP PLC LS-10 (RTQ1) pay dividends?

No. AVACTA GROUP PLC LS-10 does not pay a dividend.

What is AVACTA GROUP PLC LS-10 (RTQ1) beta (volatility) score?

AVACTA GROUP PLC LS-10 has a beta of -0.109, indicating lower volatility than the overall market.